Global Gastrointestinal Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Apr-2017
No. of pages: 700
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Gastrointestinal Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the gastrointestinal partnering deals and agreements entered into by the worlds leading healthcare companies

Global Gastrointestinal Partnering 2010 to 2017 provides the full collection of Gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Gastrointestinal partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Gastrointestinal partnering agreement structure

Gastrointestinal partnering contract documents

Top Gastrointestinal deals by value

Most active Gastrointestinal dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.

The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Gastrointestinal dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Gastrointestinal dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Gastrointestinal deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Gastrointestinal deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2010. The chapter is organized by specific Gastrointestinal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gastrointestinal partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gastrointestinal technologies and products.

Report scope

Global Gastrointestinal Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Gastrointestinal trends and structure of deals entered into by leading companies worldwide.

Global Gastrointestinal Partnering 2010 to 2017 includes:

Trends in Gastrointestinal dealmaking in the biopharma industry since 2010

Analysis of Gastrointestinal deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Gastrointestinal deal contract documents

Comprehensive access to over 3500 Gastrointestinal deal records

The leading Gastrointestinal deals by value since 2010

Most active Gastrointestinal dealmakers since 2010

The report includes deals for the following indications: Appendicitis, Celiac disease, Esophageal reflux, Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation, Diarrhea, Jaundice, Vomitting, plus other gastrointestinal indications.

In Global Gastrointestinal Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Gastrointestinal Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 400 gastrointestinal deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Gastrointestinal Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Gastrointestinal deal trends since 2010

Access Gastrointestinal deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Gastrointestinal partner companies

Comprehensive access to over 750 links to actual Gastrointestinal deals entered into by the world's biopharma companies

Indepth review of Gastrointestinal deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Gastrointestinal opportunities

Uncover companies actively partnering Gastrointestinal opportunities

Global Gastrointestinal Partnering 2010-2017: Deal trends, players and financials

Table of Contents
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gastrointestinal dealmaking
2.1. Introduction
2.2. Gastrointestinal partnering over the years
2.3. Gastrointestinal partnering by deal type
2.4. Gastrointestinal partnering by industry sector
2.5. Gastrointestinal partnering by stage of development
2.6. Gastrointestinal partnering by technology type
2.7. Gastrointestinal partnering by therapeutic indication

Chapter 3 -Financial deal terms for Gastrointestinal partnering
3.1. Introduction
3.2. Disclosed financials terms for Gastrointestinal partnering
3.3. Gastrointestinal partnering headline values
3.4. Gastrointestinal deal upfront payments
3.5. Gastrointestinal deal milestone payments
3.6. Gastrointestinal royalty rates

Chapter 4 - Leading Gastrointestinal deals and dealmakers
4.1. Introduction
4.2. Most active in Gastrointestinal partnering
4.3. List of most active dealmakers in Gastrointestinal
4.4. Top Gastrointestinal deals by value

Chapter 5 - Gastrointestinal contract document directory
5.1. Introduction
5.2. Gastrointestinal partnering deals where contract document available

Chapter 6 - Gastrointestinal dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Gastrointestinal therapeutic target

Appendices

Appendix 1 - Directory of Gastrointestinal deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Gastrointestinal deals by deal type 2010 to 2017
Appendix 3 - Directory of Gastrointestinal deals by stage of development 2010 to 2017
Appendix 4 - Directory of Gastrointestinal deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Gastrointestinal partnering since 2010
Figure 2: Gastrointestinal partnering by deal type since 2010
Figure 3: Gastrointestinal partnering by industry sector since 2010
Figure 4: Gastrointestinal partnering by stage of development since 2010
Figure 5: Gastrointestinal partnering by technology type since 2010
Figure 6: Gastrointestinal partnering by indication since 2010
Figure 7: Gastrointestinal deals with a headline value
Figure 8: Gastrointestinal deals with upfront payment values
Figure 9: Gastrointestinal deals with milestone payment
Figure 10: Gastrointestinal deals with royalty rates
Figure 11: Active Gastrointestinal dealmaking activity- 2010 to 2017
Figure 12: Top Gastrointestinal deals by value since 2010
  • Global Diarrhea Drug Sales Market Report 2017
    Published: 16-Aug-2017        Price: US 4000 Onwards        Pages: 106
    In this report, the global Diarrhea Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Diarrhea Drug for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan -......
  • Global Diarrhea Drug Market Research Report 2017
    Published: 09-Aug-2017        Price: US 2900 Onwards        Pages: 104
    In this report, the global Diarrhea Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Diarrhea Drug in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan......
  • Global and United States Digestive system agents In-Depth Research Report 2017-2022
    Published: 04-Aug-2017        Price: US 3190 Onwards        Pages: 126
    The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2016 to 2022. This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Digestive system agents industry. Major Companies - Sigma-Tau Industrie Farmaceutiche Riunite S.p.A......
  • Global Opioid Induced Constipation Drug Market Forecast 2017-2025
    Published: 01-Aug-2017        Price: US 2500 Onwards        Pages: 113
    Key Findings Global Opioid Induced Constipation (OIC) drug market is estimated to grow at a CAGR of 4.88% during the forecast period of 2017 - 2025. The major drivers responsible for the market growth are: • Rising use of opioid • Increasing geriatric population • Increasing opioid prescription in North America and Europe • Detection of safety threats • Easy availability of improved and effective OIC drugs Some of the commonly prescribed opioids ......
  • Asia-Pacific Opioid Induced Constipation Drug Market Forecast 2017-2025
    Published: 01-Aug-2017        Price: US 1250 Onwards        Pages: 54
    Key Findings The Asia-Pacific Opioid Constipation Drug market is estimated to grow at a CAGR of 5.07% during the forecast period of 2017-2025. The market worth is expected to increase from $233 million in 2016 and reach $361.88 million by 2025. The ease in the availability of new and improved drugs and the growing geriatric population are currently driving the Asian Market. Market Insights The Asian market can be classified on the basis of drug type and prescription type. Th......
  • Europe opioid Induced Constipation Drug Market Forecast 2017-2025
    Published: 01-Aug-2017        Price: US 1250 Onwards        Pages: 52
    Key Findings The Europe opioid constipation drug market is expected to grow at a CAGR of 4.00% during the forecast period of 2017-2025. The market value is predicted to increase from $896.3 million in 2016 and reach up to $1273.34 million by 2025. Market Insights The Europe opioid constipation drug market is mainly driven by the increasing opioids prescription in the region. The market can be segmented into two criteria. First is the market by drug type that includes drugs s......
  • North America Opioid Induced Constipation Drug Market Forecast 2017-2025
    Published: 01-Aug-2017        Price: US 1250 Onwards        Pages: 51
    Key Findings The North America opioid induced constipation drug market is expected to be the fastest growing market during the forecast period of 2017-2025 with an expected CAGR growth of 5.72%. The revenue generated by the market is expected to increase from $840.4 million in 2016 and reach $1382.73 million by 2025. Market Insights The North American OIC drug market is segmented on the basis of the type of prescription and the type of drug. The prescription type market is f......
  • Global Digestive system agents Detailed Analysis Report 2017-2022
    Published: 31-Jul-2017        Price: US 3250 Onwards        Pages: 125
    This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Digestive system agents industry. This report splits Digestive system agents market by Promoting ingestion drugs, by Antispasmodic and gastro-kinetic agent, by Cathartic and antidiarrheal drugs, by Others, which covers the history data information fr......
  • Global Digestive system agents Market Research Report 2017-2022 by Players, Regions, Product Types & Applications
    Published: 31-Jul-2017        Price: US 2380 Onwards        Pages: 115
    The global Digestive system agents market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. This report offers an overview of the market trends, drivers, and barriers with respect to the Digestive system agents market. It also provides a detailed overview of the market of different regions across United States, Europe, China, Japan, India, Southeast Asia and Others. The report categorizes......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs